Volitionrx (VNRX)
Volitionrx on one page: short interest, daily short volume, fails to deliver, large holders, financials, earnings dates and insider trades. Listed on NYSE, classified by the SEC as in vitro & in vivo diagnostic substances.
1.2M
Short interest
settlement 2026-09-30
1.0
Days to cover
unchanged vs prior
37.5%
Short share of volume
2026-10-12
11,573
Fails to deliver
settlement 2026-09-14
Tue 13 Oct
Next earnings
estimated date
$0
Insider flow, 90 days
0 buys, 0 sells
As of 2026-10-12.
Short interest
FINRA, twice a month. The newest 24 settlements in the table, 48 in the chart. JSONAs of 30 September 2026, short interest in VNRX is 1,196,849 shares, down 1,027,201 shares over the last month. Over the last 48 readings it ranged from 177,966 shares (15 August 2025) to 8,074,406 shares (31 March 2026). At the reported average volume of 4.4M shares a day that is 1.0 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/vnrx" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-09-30 | 1,196,849 | +19.1% | 4,427,440 | 1.00 |
| 2026-09-15 | 1,004,963 | -54.8% | 1,733,578 | 1.00 |
| 2026-08-31 | 2,224,050 | +225.2% | 40,219,957 | 1.00 |
| 2026-08-14 | 683,892 | +27.0% | 1,617,782 | 1.00 |
| 2026-07-31 | 538,529 | +101.2% | 308,439 | 1.75 |
| 2026-07-15 | 267,687 | -17.0% | 212,123 | 1.26 |
| 2026-06-30 | 322,418 | +26.9% | 296,836 | 1.09 |
| 2026-06-15 | 254,125 | -34.7% | 424,498 | 1.00 |
| 2026-05-29 | 389,005 | -7.4% | 293,228 | 1.33 |
| 2026-05-15 | 420,084 | +56.1% | 308,361 | 1.36 |
| 2026-04-30 | 269,068 | -96.2% | 193,588 | 1.39 |
| 2026-04-15 | 7,087,765 | -12.2% | 4,216,243 | 1.68 |
| 2026-03-31 | 8,074,406 | +491.8% | 47,461,105 | 1.00 |
| 2026-03-13 | 1,364,488 | -4.0% | 1,288,463 | 1.06 |
| 2026-02-27 | 1,421,157 | -38.1% | 2,150,188 | 1.00 |
| 2026-02-13 | 2,294,782 | +46.6% | 2,140,767 | 1.07 |
| 2026-01-30 | 1,565,335 | +40.0% | 2,494,809 | 1.00 |
| 2026-01-15 | 1,118,479 | +65.3% | 2,519,261 | 1.00 |
| 2025-12-31 | 676,713 | +24.4% | 2,688,706 | 1.00 |
| 2025-12-15 | 543,884 | -48.7% | 1,476,646 | 1.00 |
| 2025-11-28 | 1,060,995 | +192.4% | 4,483,835 | 1.00 |
| 2025-11-14 | 362,805 | +32.9% | 825,693 | 1.00 |
| 2025-10-31 | 272,971 | +2.6% | 1,257,101 | 1.00 |
| 2025-10-15 | 266,027 | -20.8% | 647,308 | 1.00 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 12 October 2026, the short share of VNRX volume is 37.5%, up 15.9 points over the last five sessions. Over the last 30 readings it ranged from 21.6% (5 October 2026) to 68.6% (15 September 2026). The latest reading is 2.2 points below the 30-session average of 39.7%, on 452K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-10-12 | 169K | 452K | 37.5% | 12,800 |
| 2026-10-09 | 140K | 626K | 22.3% | 0 |
| 2026-10-08 | 148K | 485K | 30.5% | 1,000 |
| 2026-10-07 | 345K | 955K | 36.1% | 51 |
| 2026-10-06 | 94K | 293K | 32.0% | 0 |
| 2026-10-05 | 85K | 397K | 21.6% | 0 |
| 2026-10-02 | 257K | 1.0M | 24.9% | 0 |
| 2026-10-01 | 2.8M | 6.6M | 41.6% | 0 |
| 2026-09-30 | 355K | 771K | 46.0% | 4,430 |
| 2026-09-29 | 711K | 1.5M | 47.2% | 0 |
| 2026-09-28 | 116K | 496K | 23.4% | 0 |
| 2026-09-25 | 1.0M | 2.0M | 52.4% | 345 |
| 2026-09-24 | 191K | 549K | 34.9% | 9,897 |
| 2026-09-23 | 725K | 1.9M | 37.7% | 42,810 |
| 2026-09-22 | 441K | 1.1M | 39.3% | 28,000 |
| 2026-09-21 | 315K | 796K | 39.5% | 59,491 |
| 2026-09-18 | 691K | 2.3M | 29.6% | 197,792 |
| 2026-09-17 | 2.4M | 4.3M | 56.5% | 12,908 |
| 2026-09-16 | 194K | 791K | 24.5% | 692 |
| 2026-09-15 | 867K | 1.3M | 68.6% | 0 |
| 2026-09-14 | 547K | 904K | 60.5% | 83,471 |
| 2026-09-11 | 251K | 574K | 43.7% | 4,157 |
| 2026-09-10 | 213K | 450K | 47.4% | 0 |
| 2026-09-09 | 732K | 1.2M | 59.4% | 262 |
| 2026-09-08 | 260K | 578K | 45.0% | 169 |
| 2026-09-04 | 319K | 691K | 46.2% | 43,087 |
| 2026-09-03 | 350K | 1.2M | 29.3% | 49,488 |
| 2026-09-02 | 416K | 1.0M | 40.0% | 57,960 |
| 2026-09-01 | 401K | 1.2M | 34.3% | 135,970 |
| 2026-08-31 | 889K | 2.3M | 38.3% | 229,717 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 14 September 2026, the fails-to-deliver balance in VNRX is 11,573 shares, down 46,122 shares over the last settlement date. Over the last 30 readings it ranged from 26 shares (16 July 2026) to 7,068,460 shares (28 August 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-09-14 | 11,573 | $0.31 | $4K |
| 2026-09-10 | 57,695 | $0.34 | $20K |
| 2026-09-08 | 1,712 | $0.35 | $599 |
| 2026-09-01 | 102,673 | $0.43 | $44K |
| 2026-08-31 | 620,312 | $0.45 | $279K |
| 2026-08-28 | 7,068,460 | $0.50 | $3.5M |
| 2026-08-27 | 2,818,903 | $0.34 | $958K |
| 2026-08-25 | 3,473 | $0.39 | $1K |
| 2026-08-14 | 3,870 | $0.63 | $2K |
| 2026-08-11 | 19,972 | $0.77 | $15K |
| 2026-08-10 | 49,568 | $0.78 | $39K |
| 2026-08-06 | 98,847 | $0.80 | $79K |
| 2026-08-05 | 23,766 | $0.79 | $19K |
| 2026-08-04 | 12,457 | $0.80 | $10K |
| 2026-08-03 | 5,724 | $0.72 | $4K |
| 2026-07-31 | 13,415 | $0.80 | $11K |
| 2026-07-30 | 12,109 | $0.77 | $9K |
| 2026-07-29 | 28,808 | $0.85 | $24K |
| 2026-07-28 | 16,626 | $0.88 | $15K |
| 2026-07-24 | 3,688 | $1.08 | $4K |
| 2026-07-23 | 5,265 | $1.04 | $5K |
| 2026-07-21 | 1,991 | $1.13 | $2K |
| 2026-07-16 | 26 | $1.18 | $31 |
| 2026-07-15 | 564 | $1.27 | $716 |
| 2026-07-14 | 1,850 | $1.30 | $2K |
| 2026-07-13 | 1,301 | $1.35 | $2K |
| 2026-07-09 | 7,177 | $1.35 | $10K |
| 2026-07-08 | 2,661 | $1.40 | $4K |
| 2026-07-07 | 571 | $1.35 | $771 |
| 2026-07-01 | 4,808 | $1.35 | $6K |
Insider trades
SEC Form 4, newest first, 50 of 100 shown. JSONNo open-market insider trades were reported for VNRX in the last 90 days. The most recent filings are listed below. Latest filing: Michel Gaetan (Chief Operating Officer) on 2026-09-28.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-09-28 | Michel Gaetan | Chief Operating Officer | Tax withholding | 608 | $0.25 | $154 | 12K |
| 2026-09-28 | Forterre Gael | Chief Commercial Officer | Tax withholding | 284 | $0.25 | $72 | 16K |
| 2026-03-17 | Micallef Jacob Vincent | Chief Scientific Officer | Tax withholding | 5K | $0.19 | $1K | 572K |
| 2026-03-17 | Plummer Nicholas | GC - Volition Diagnostics | Tax withholding | 7K | $0.19 | $1K | 407K |
| 2026-03-17 | Rootsaert Rodney Gerard | Secretary | Tax withholding | 4K | $0.19 | $750 | 274K |
| 2026-03-17 | Forterre Gael | Chief Commercial Officer | Tax withholding | 5K | $0.19 | $998 | 331K |
| 2026-03-01 | Plummer Nicholas | GC - Volition Diagnostics | Tax withholding | 6K | $0.21 | $1K | 414K |
| 2026-03-01 | Forterre Gael | Chief Commercial Officer | Tax withholding | 2K | $0.21 | $479 | 337K |
| 2026-03-01 | Rootsaert Rodney Gerard | Secretary | Tax withholding | 3K | $0.21 | $697 | 278K |
| 2026-02-26 | Innes Guy Archibald | Director | Grant | 178K | $0.00 | $0 | 1.3M |
| 2026-02-26 | Micallef Jacob Vincent | Chief Scientific Officer | Grant | 149K | $0.00 | $0 | 577K |
| 2026-02-26 | Kway Jasmine | CEO - Singapore Volition | Grant | 173K | $0.00 | $0 | 419K |
| 2026-02-26 | Nguyen Kim | Director | Grant | 178K | $0.00 | $0 | 306K |
| 2026-02-26 | Plummer Nicholas | GC - Volition Diagnostics | Grant | 187K | $0.00 | $0 | 420K |
| 2026-02-26 | Rootsaert Rodney Gerard | Secretary | Grant | 119K | $0.00 | $0 | 281K |
| 2026-02-26 | Hughes Terig | Chief Financial Officer | Grant | 202K | $0.00 | $0 | 685K |
| 2026-02-26 | Batchelor Ann-Louise | Group Chief Marketing Officer | Grant | 142K | $0.00 | $0 | 324K |
| 2026-02-26 | Reynolds Cameron John | President and CEO | Grant | 486K | $0.00 | $0 | 3.1M |
| 2026-02-26 | Rubin Ethel | Director | Grant | 178K | $0.00 | $0 | 253K |
| 2026-02-26 | Forterre Gael | Chief Commercial Officer | Grant | 149K | $0.00 | $0 | 339K |
| 2026-02-01 | Plummer Nicholas | GC - Volition Diagnostics | Tax withholding | 6K | $0.29 | $2K | 233K |
| 2026-02-01 | Rootsaert Rodney Gerard | Secretary | Tax withholding | 3K | $0.29 | $927 | 162K |
| 2026-02-01 | Forterre Gael | Chief Commercial Officer | Tax withholding | 2K | $0.29 | $583 | 190K |
| 2026-01-22 | Kway Jasmine | CEO - Singapore Volition | Grant | 42K | $0.00 | $0 | 246K |
| 2026-01-22 | Nguyen Kim | Director | Grant | 12K | $0.00 | $0 | 128K |
| 2026-01-22 | Henshall Mickie | Director | Grant | 12K | $0.00 | $0 | 44K |
| 2026-01-22 | Plummer Nicholas | GC - Volition Diagnostics | Grant | 45K | $0.00 | $0 | 239K |
| 2026-01-22 | Micallef Jacob Vincent | Chief Scientific Officer | Grant | 35K | $0.00 | $0 | 428K |
| 2026-01-22 | Rootsaert Rodney Gerard | Secretary | Grant | 28K | $0.00 | $0 | 165K |
| 2026-01-22 | Butera Salvatore Thomas | CEO - Volition Veterinary | Grant | 53K | $0.00 | $0 | 375K |
| 2026-01-22 | Barnes Phillip | Director | Grant | 12K | $0.00 | $0 | 67K |
| 2026-01-22 | Hughes Terig | Chief Financial Officer | Grant | 49K | $0.00 | $0 | 483K |
| 2026-01-22 | Batchelor Ann-Louise | Group Chief Marketing Officer | Grant | 34K | $0.00 | $0 | 182K |
| 2026-01-22 | STILL TIMOTHY I | Director | Grant | 90K | $0.00 | $0 | 1.6M |
| 2026-01-22 | Colman Alan | Director | Grant | 12K | $0.00 | $0 | 257K |
| 2026-01-22 | Reynolds Cameron John | President and CEO | Grant | 75K | $0.00 | $0 | 2.6M |
| 2026-01-22 | Forterre Gael | Chief Commercial Officer | Grant | 38K | $0.00 | $0 | 192K |
| 2026-01-22 | Innes Guy Archibald | Director | Grant | 12K | $0.00 | $0 | 1.1M |
| 2026-01-22 | Rubin Ethel | Director | Grant | 12K | $0.00 | $0 | 75K |
| 2025-11-17 | Reynolds Cameron John | President and CEO | Buy | 20K | $0.35 | $7K | 2.6M |
| 2025-11-01 | Forterre Gael | Chief Commercial Officer | Tax withholding | 2K | $0.43 | $754 | 154K |
| 2025-11-01 | Butera Salvatore Thomas | CEO - Volition Veterinary | Tax withholding | 5K | $0.43 | $2K | 322K |
| 2025-11-01 | Rootsaert Rodney Gerard | Secretary | Tax withholding | 3K | $0.43 | $1K | 137K |
| 2025-11-01 | Plummer Nicholas | GC - Volition Diagnostics | Tax withholding | 6K | $0.43 | $2K | 194K |
| 2025-11-01 | Retter Andrew | Chief Medical Officer | Tax withholding | 5K | $0.43 | $2K | 147K |
| 2025-10-14 | STILL TIMOTHY I | Director | Buy | 48K | $0.51 | $25K | 1.5M |
| 2025-10-14 | Innes Guy Archibald | Director | Buy | 96K | $0.51 | $49K | 1.1M |
| 2025-10-14 | Reynolds Cameron John | President and CEO | Buy | 110K | $0.51 | $56K | 2.5M |
| 2025-10-04 | Micallef Jacob Vincent | Chief Scientific Officer | Tax withholding | 6K | $0.65 | $4K | 393K |
| 2025-10-04 | Michel Gaetan | Chief Operating Officer | Tax withholding | 12K | $0.65 | $8K | 257K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON3 holders report 5% or more of VNRX in their latest filing, all on Schedule 13D (active intent). The largest reported stake is Fatima Dickey at 5.9% of the class (1,650,505 shares), filed 2026-09-16 for an event on 2026-09-15.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-09-16 | 13D/Ano. 1 | Fatima Dickeyindividual | 1.7M | 5.9% | 2026-09-15 |
| 2026-09-16 | 13D/Ano. 1 | Lagoda Investment Management, LLCparent holding company | 1.7M | 5.9% | 2026-09-15 |
| 2026-09-16 | 13D/Ano. 1 | Lagoda Investment Management, L.P.investment adviser | 1.7M | 5.9% | 2026-09-15 |
| 2026-02-17 | 13G/Ano. 5 | Armistice Capital, LLCinvestment adviser, other entity | 6.4M | 5.0% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 5 | Steven Boydparent holding company, individual | 6.4M | 5.0% | 2025-12-31 |
Financials
SEC XBRL, as filed. JSONIn Q2 FY 2026 (quarter ended 2026-06-30) Volitionrx reported revenue of $399K, down 2.0% from the same quarter a year earlier, and net loss of $7.3M (-0.85 diluted EPS). In FY 2025 it generated -$19.7M of operating cash flow. As of 2026-06-30, cash was $2.8M against $7.1M of debt.
- Cash
- $2.8M
- Debt
- $7.1M
- Equity
- -$32.2M
- Total assets
- $8.3M
- Shares outstanding
- 13,649,384
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q2 FY 2026 | 2026-06-30 | $399K | -$7.3M | -1837.7% | -0.85 |
| Q1 FY 2026 | 2026-03-31 | $985K | -$6.7M | -676.6% | -0.97 |
| Q4 FY 2025derived | 2025-12-31 | $447K | -$6.3M | -1402.8% | n/a |
| Q3 FY 2025 | 2025-09-30 | $627K | -$5.4M | -857.4% | -0.05 |
| Q2 FY 2025 | 2025-06-30 | $407K | -$6.3M | -1545.2% | -1.22 |
| Q1 FY 2025 | 2025-03-31 | $246K | -$5.4M | -2201.3% | -1.12 |
| Q4 FY 2024derived | 2024-12-31 | $192K | -$5.8M | -3022.8% | n/a |
| Q3 FY 2024 | 2024-09-30 | $475K | -$5.8M | -1226.8% | -0.07 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $1.7M | -$23.4M | -$19.7M | $90K | n/a | n/a |
| FY 2024 | 2024-12-31 | $1.2M | -$27.0M | -$25.9M | $277K | $0 | n/a |
| FY 2023 | 2023-12-31 | $775K | -$35.7M | -$18.1M | $1.1M | $32K | n/a |
| FY 2022 | 2022-12-31 | $306K | -$30.6M | -$15.3M | $1.6M | $0 | n/a |
| FY 2021 | 2021-12-31 | $90K | -$27.0M | -$20.9M | $974K | n/a | n/a |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-08-11 from the cover page.
What this page is
Volitionrx in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Volitionrx (VNRX), SEC CIK 93314, listed on NYSE, classified by the SEC as in vitro & in vivo diagnostic substances. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-09-30.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-10-12.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-09-14.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-09-16.JSON and CSV
- Financials
- SEC EDGAR 10-K and 10-Q filingsSource: SEC.Weekly; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-13.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-09-28.JSON and CSV
- Company record
- EDGAR filing index for CIK 93314Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as in vitro & in vivo diagnostic substances
Other company pages
Datasets
Frequently Asked Questions
How much of VNRX is sold short?
What is VNRX's daily short volume?
Does VNRX have fails to deliver?
Are VNRX insiders buying or selling?
Who owns 5% or more of VNRX?
What did VNRX report last quarter?
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.